Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF): The International Steering Committee in behalf of the MERIT-HF study group

American Journal of Cardiology

Volumn 80, Issue 9 B, 1997, Pages

  Fagerberg, B ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL; PLACEBO;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; DRUG SCREENING; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; ORGANIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 0030668967     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Guidelines for the diagnosis of heart failure. Eur Heart J. 16:1995;741-751.
2. Cohn JN. The management of chronic heart failure. N Engl J Med. 335:1996;490-498.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
4. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Economics. 6:1993;99-110.
5. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 82:1990;1730-1736.
6. Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure should they be used and how? Eur Heart J. 17:1996;1629-1639.
7. A randomized trial of beta-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
8. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson Å. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
9. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
10. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
11. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med. 334:1996;1396-1397.
12. Eichhorn EJ, Heesch CM, Barnet J, Alvarez LG, Fass SM, Grayburn PA, Hatfield B, Marcoux L, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy a randomized, double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
13. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PF, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
14. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 79:1989;483-490.
15. Andersson B, Blomström-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-blockade in severe heart failure. J Am Coll Cardiol. 18:1991;1059-1066.
16. Waagstein F. Metoprolol in addition to ACE-inhibitors causes regression of left ventricular dilatation and increases exercise ejection fraction in ischemic cardiomyopathy (Abstr.) . J Am Coll Cardiol. 29:(suppl A):1997;206A.
17. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction tolerability and survival effects . Am J Cardiol. 71:1993;39C-44C.
18. Hjalmarson Å, Elmfeldt D, Herlitz J. Effect on mortality of metoprolol in acute myocardial infarction a double-blind, randomised trial . Lancet. ii:1981;823-827.
19. Metoprolol in acute myocardial infarction (MIAMI) a randomized, placebo-controlled, international trial . Eur Heart J. 6:1985;199-226.
20. Herlitz J, Hjalmarson Å, Waagstein F. Effect of metoprolol among patients with suspected acute myocardial infarction and left ventricular dysfunction (Abstr.) . Eur Heart J. 17:(abstr suppl):1997;514.
21. Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol - metoprolol CR/XL. Eur J Clin Pharmacol. 33:(abstr suppl):1988;S3-S7.
22. Abrahamsson B, Lucker P, Olofsson B, Regardh CG, Sandberg A, Wieselgren I, Bergstrand R. The relationship between metoprolol plasma concentration and beta-1-blockade in healthy subjects a study on conventional metoprolol and metoprolol CR/ZOK formulations . J Clin Pharmacol. 30:1990;S46-S54.